- Home
- MNOV vs IFRX Comparison
MNOV vs IFRX Comparison
Compare MNOV & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- IFRX
- Stock Information
- Founded
- MNOV 2000
- IFRX 2007
- Country
- MNOV United States
- IFRX Germany
- Employees
- MNOV N/A
- IFRX N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- IFRX Health Care
- Exchange
- MNOV Nasdaq
- IFRX Nasdaq
- Market Cap
- MNOV 76.0M
- IFRX 65.8M
- IPO Year
- MNOV 2005
- IFRX 2017
- Fundamental
- Price
- MNOV $1.49
- IFRX $1.20
- Analyst Decision
- MNOV Strong Buy
- IFRX Strong Buy
- Analyst Count
- MNOV 1
- IFRX 2
- Target Price
- MNOV $9.00
- IFRX $9.00
- AVG Volume (30 Days)
- MNOV 14.9K
- IFRX 334.7K
- Earning Date
- MNOV 05-08-2025
- IFRX 05-07-2025
- Dividend Yield
- MNOV N/A
- IFRX N/A
- EPS Growth
- MNOV N/A
- IFRX N/A
- EPS
- MNOV N/A
- IFRX N/A
- Revenue
- MNOV N/A
- IFRX $171,642.00
- Revenue This Year
- MNOV N/A
- IFRX $106.72
- Revenue Next Year
- MNOV N/A
- IFRX $66.89
- P/E Ratio
- MNOV N/A
- IFRX N/A
- Revenue Growth
- MNOV N/A
- IFRX 162.79
- 52 Week Low
- MNOV $1.12
- IFRX $0.82
- 52 Week High
- MNOV $2.55
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- MNOV 54.28
- IFRX 52.98
- Support Level
- MNOV $1.36
- IFRX $0.82
- Resistance Level
- MNOV $1.52
- IFRX $1.12
- Average True Range (ATR)
- MNOV 0.10
- IFRX 0.13
- MACD
- MNOV 0.03
- IFRX 0.05
- Stochastic Oscillator
- MNOV 92.31
- IFRX 84.30
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.